Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Latest News

Ligand Acquires Assets of Novan, Inc. for $12.2 Million

Read More

Ligand Appoints Martine Zimmermann to its Board of Directors

Read More

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Read More

Recent Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range